Is Egrifta (Tesamorelin) Legal in Georgia?

Federal Legal Status of Tesamorelin

Tesamorelin is a synthetic analog of growth-hormone-releasing hormone (GHRH). The FDA granted it New Drug Application approval (NDA 022505) in November 2010 under the brand name Egrifta, specifically for reducing excess visceral fat in HIV-infected adults with lipodystrophy. A 2014 supplemental approval expanded labeling to Egrifta SV, a reformulated version. Because it carries an approved NDA, tesamorelin is a legal prescription drug in all 50 states, including Georgia, under the Federal Food, Drug, and Cosmetic Act. The FDA's current drug database confirms NDA 022505 as active.

How FDA Approval Changes the Legal Picture

Most peptides sold online exist in a gray zone because they lack any approved application. Tesamorelin does not share that ambiguity. A licensed Georgia physician can write a prescription for Egrifta SV through normal pharmacy channels without any special federal waiver. The DEA has not scheduled tesamorelin under the Controlled Substances Act, so neither the prescriber nor the patient faces DEA reporting requirements specific to this drug.

Bulk-Drug-Substance List and Compounding

The FDA maintains a list of bulk drug substances that 503A pharmacies may use for compounding. Tesamorelin's FDA-approved status does not automatically bar compounding, but FDA guidance states that compounders should not prepare copies of commercially available drugs unless a documented patient-specific reason exists. Prescribers who document a clinical rationale, such as a patient's need for a different concentration or diluent, may still work with a 503A pharmacy to obtain a compounded tesamorelin formulation.

Georgia State Law Framework

Georgia does not have a stand-alone statute that singles out tesamorelin or any peptide by name. The state's legal framework for prescription drugs flows from three sources: the Georgia Pharmacy Practice Act (O.C.G.A. Title 26), the Georgia Composite Medical Board's rules on prescribing, and federal law as adopted by reference. All three are consistent with FDA rules rather than in conflict with them.

Georgia Pharmacy Board Rules

The Georgia State Board of Pharmacy licenses both traditional 503A pharmacies and, by registration, 503B outsourcing facilities operating in the state. The Board's compounding rules align with USP Chapter 795 (non-sterile) and Chapter 797 (sterile), which govern injectables like tesamorelin. A 503A pharmacy in Georgia may compound tesamorelin for an identified patient when a licensed prescriber submits a valid prescription that documents a legitimate medical purpose.

Georgia Medical Practice Act and Prescriber Authority

Under O.C.G.A. § 43-34-21, Georgia physicians hold broad authority to prescribe any non-scheduled drug within the bounds of good medical practice. The Georgia Composite Medical Board has published guidance confirming that off-label prescribing is legal when the prescriber can document clinical justification. Tesamorelin prescribed for non-HIV conditions, such as age-related growth-hormone deficiency or body-composition optimization in non-HIV patients, falls under this off-label authority.

No Georgia-Specific Scheduling or Prohibition

A review of Georgia's Controlled Substances list (O.C.G.A. § 16-13-25 through § 16-13-29) confirms tesamorelin is absent from all five schedules. This means possession with a valid prescription carries no state-level controlled-substance penalty, and prescribers face no state DEA-equivalent reporting burden for this drug.

Clinical Evidence Supporting Tesamorelin Use

Understanding why clinicians prescribe tesamorelin off-label requires a brief look at the trial data. The drug's approval rested on two key randomized controlled trials published in the New England Journal of Medicine.

LIPO-010 and LIPO-011 Key Trials

In LIPO-010 and LIPO-011 (combined N=816 HIV-positive adults), Falutz et al. Showed that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 18% versus 5% placebo at 26 weeks (P<0.001). Trunk fat also declined significantly. IGF-1 levels rose within normal limits, and fasting glucose changes were modest, with HbA1c remaining stable in most participants.

A follow-up 52-week extension published in the Annals of Internal Medicine confirmed that VAT reduction was maintained with continued therapy and largely reversed within 26 weeks of discontinuation. This reversibility is relevant to informed-consent discussions Georgia prescribers must conduct.

IGF-1 Monitoring Requirement

The FDA-approved Egrifta SV label states that IGF-1 should be checked at baseline and during treatment, with dose interruption if IGF-1 exceeds the upper limit of normal. This monitoring requirement applies regardless of whether the prescription is for the approved HIV indication or an off-label one. Georgia clinicians prescribing through telehealth must include remote IGF-1 monitoring in the care plan.

Tesamorelin in Non-HIV Populations

Off-label use in non-HIV adults with abdominal obesity has been studied. A trial by Stanley et al. (N=49) published in the Journal of Clinical Endocrinology and Metabolism found that tesamorelin 2 mg/day reduced VAT by 18.3% versus 4.4% placebo at 52 weeks (P<0.001) in non-HIV adults with abdominal obesity. The effect size mirrored the HIV-positive cohorts. This is one of the primary data points Georgia prescribers cite when documenting clinical rationale for off-label use.

A separate 2012 paper by Falutz et al. In Metabolism examined cardiometabolic markers, finding that triglycerides fell by approximately 50 mg/dL in tesamorelin-treated subjects versus placebo, a finding relevant to prescribers managing patients with metabolic syndrome alongside body-composition goals.

How to Get Egrifta (Tesamorelin) Legally in Georgia

Getting tesamorelin legally in Georgia requires three things: a valid prescriber-patient relationship, a written prescription, and a licensed pharmacy. Each step is governed by existing law.

Step 1: Establish Care with a Licensed Georgia Prescriber

Any Georgia-licensed physician (MD or DO), nurse practitioner, or physician assistant with prescribing authority may write for tesamorelin. The prescriber must conduct a clinical evaluation, document the indication (approved or off-label with rationale), review contraindications (active malignancy, hypersensitivity to mannitol, pregnancy), and establish a monitoring plan. The Endocrine Society's clinical practice guidelines on adult growth hormone deficiency provide a recognized framework that Georgia prescribers commonly use to justify GHRH-axis therapy.

Step 2: Obtain the Prescription Through a Licensed Pharmacy

Two channels exist.

Brand Egrifta SV: A prescriber sends the prescription to any Georgia-licensed retail or specialty pharmacy. Theratechnologies distributes Egrifta SV through specialty pharmacy networks. Insurance coverage for the HIV-approved indication is common under major payers; off-label coverage varies.

Compounded tesamorelin: A prescriber who documents a patient-specific need, such as a preservative-free formulation or a concentration not commercially available, may direct the prescription to a Georgia-licensed 503A compounding pharmacy. FDA guidance on 503A pharmacies requires that the preparation not be a copy of a commercially available product unless the prescriber documents a clinical difference. The prescription must be patient-specific; bulk distribution without a prescription is not lawful.

Step 3: Telehealth Prescribing in Georgia

Georgia law permits telehealth prescribing for non-controlled substances after a prescriber establishes a valid patient-provider relationship, which Georgia's telehealth statute (O.C.G.A. § 33-24-56.4) allows through synchronous audio-visual evaluation. This means a Georgia resident can complete an intake, lab review, and clinical consultation via video with a licensed prescriber and receive a tesamorelin prescription without an in-person visit, provided the standard of care is met.

The HealthRX clinical team uses a four-checkpoint framework for telehealth tesamorelin prescribing in Georgia: (1) baseline IGF-1 and fasting glucose drawn at a local lab before the first prescription is sent, (2) written documentation of indication and any off-label rationale in the chart, (3) a signed informed-consent form covering the reversibility of fat loss on discontinuation and the need for monitoring, and (4) a 12-week IGF-1 recheck scheduled at intake before the second prescription is authorized. This process satisfies both FDA labeling expectations and Georgia Composite Medical Board standards for telehealth prescribing.

Contraindications and Safety Considerations

Tesamorelin carries specific contraindications that Georgia prescribers must screen for regardless of the prescribing channel.

Absolute Contraindications

The Egrifta SV prescribing information lists active malignancy and disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor, head trauma, prior cranial irradiation) as absolute contraindications. Hypersensitivity to tesamorelin or mannitol is also an absolute contraindication. Pregnancy is contraindicated; tesamorelin is FDA Pregnancy Category X based on animal data showing fetal harm.

Relative Cautions

A 2013 analysis published in Diabetes Care (N=391 HIV-positive patients) found that new-onset glucose impairment occurred in approximately 4.7% of tesamorelin recipients versus 2.1% placebo at 52 weeks. Prescribers should check fasting glucose and HbA1c at baseline and at 3-month intervals. Patients with pre-existing type 2 diabetes should be monitored more frequently; tesamorelin is not contraindicated in diabetes but requires closer glycemic management.

Fluid retention, edema, arthralgia, and myalgia are the most commonly reported adverse events, consistent with GH-axis stimulation. The published safety data from pooled LIPO-010/011 showed peripheral edema in 6.3% of tesamorelin versus 2.3% placebo.

Comparing Tesamorelin to Other GHRH Peptides in Terms of Legal Standing

Georgia residents sometimes ask how tesamorelin compares legally to other growth-hormone secretagogues like sermorelin, CJC-1295, or ipamorelin.

Sermorelin

Sermorelin (GHRH 1-29) had FDA approval as Geref Diagnostic but was voluntarily withdrawn by the manufacturer in 2008. It appeared on FDA's 503A bulk-drug list for years, allowing compounding pharmacies to prepare it legally for patient-specific prescriptions. FDA's November 2023 bulk-substances guidance updated the list; prescribers and pharmacies should verify current status before prescribing compounded sermorelin.

CJC-1295 and Ipamorelin

CJC-1295 and ipamorelin have no FDA-approved NDA or ANDA. The FDA's category of "bulk drug substances that have not been approved" applies to both, placing them in a grayer regulatory position than tesamorelin. Their compounding legality depends entirely on whether they appear on an FDA-approved bulk-substance list at the time of compounding. Tesamorelin's approved NDA status gives it a fundamentally clearer legal footing.

Practical Takeaway for Georgia Patients

The clearest legal path to GHRH-axis therapy in Georgia runs through FDA-approved Egrifta SV or through a properly documented 503A compounded tesamorelin prescription. Unapproved peptides purchased from research-chemical vendors are not legal for human use regardless of state and carry federal misbranding risk under 21 U.S.C. § 331.

Insurance and Cost Considerations in Georgia

Cost matters for adherence, and Georgia patients have several options.

Commercial Insurance Coverage

Egrifta SV is covered by most commercial plans in Georgia for the FDA-approved HIV-lipodystrophy indication with prior authorization. Off-label use for non-HIV patients typically requires a step-therapy edit or a peer-to-peer appeal. Theratechnologies operates a patient-assistance program for uninsured or underinsured patients meeting income criteria.

Medicare and Medicaid

Medicare Part D covers Egrifta SV for HIV-positive enrollees meeting CMS coverage criteria. Georgia Medicaid (DCH) covers it under the HIV drug benefit for qualifying members. Off-label coverage under Medicare requires a compendia listing; as of the publication date of this article, no major compendia lists tesamorelin for non-HIV indications.

Compounded Tesamorelin Cost

Compounded tesamorelin from a licensed 503A pharmacy typically runs between $150 and $400 per month depending on concentration and pharmacy pricing. This cost is not covered by insurance in most cases. The FDA's guidance on compounding pricing does not set price caps; patients should request an itemized quote before committing.

Monitoring Protocol for Georgia Patients on Tesamorelin

Endocrine Society guidelines on growth-hormone-related therapy recommend IGF-1 measurement at baseline, 1 month after dose initiation, and every 6 months during maintenance. Tesamorelin's FDA label aligns closely with this cadence. A Georgia prescriber should coordinate with a local Quest Diagnostics or LabCorp draw site if the patient is receiving telehealth care, ensuring labs are completed before each prescription renewal.

A 2021 review in the Journal of Clinical Endocrinology and Metabolism summarized that IGF-1 levels in tesamorelin-treated patients generally stay within the age-adjusted normal range when dosing follows label recommendations of 2 mg subcutaneously daily. Dose reduction to 1 mg daily is a reasonable clinical adjustment if IGF-1 rises above normal without symptoms; the FDA label supports this approach.